Identification of Risk Factors for Bisphosphonate-Associated Atypical Femoral Fractures and Osteonecrosis of the Jaw in a Pharmacovigilance Database

被引:17
|
作者
Bejhed, Rebecca S. [1 ]
Kharazmi, Mohammad [2 ,3 ]
Hallberg, Par [4 ]
机构
[1] Uppsala Univ, Angstrom Lab, Uppsala, Sweden
[2] Uppsala Univ, Dept Surg Sci, Uppsala, Sweden
[3] Cent Hosp Vasteras, Vasteras, Sweden
[4] Uppsala Univ, Dept Med Sci, Uppsala, Sweden
关键词
bisphosphonates; osteonecrosis; atypical fracture; adverse drug reaction; drug safety; pharmacovigilance; risk factor; MEDICATION-RELATED OSTEONECROSIS; BONE; PREVENTION; ONJ;
D O I
10.1177/1060028016649368
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
BACKGROUND: Atypical femoral fractures (AFs) and osteonecrosis of the jaw (ONJ) are well-known adverse drug reactions (ADRs) associated with bisphosphonates. To prevent these ADRs and to aid in the search for pathogenic mechanisms, knowledge of risk factors can be helpful. Objective: To identify risk factors for bisphosphonate-related ONJ and AF. Methods: In this case-control study of reports of bisphosphonate-related ADRs from February 16, 1984, to October 16, 2013, in the Swedish national database of ADRs, we compared characteristics for cases of ONJ (n = 167) and AF (n = 55) with all other bisphosphonate-related ADRs (n = 565) with regard to demographic variables, clinical characteristics, and concomitant drug treatments. We adjusted for multiple comparisons with Bonferroni correction. Results: Time to onset of ADRs differed statistically significantly between cases of AF and controls (2156 vs 111 days). For ONJ versus controls, differences were statistically significant for time to onset (1240 vs 111 days), intravenous administration (40% vs 20%), dental procedures (49% vs 0.2%) and prostheses (5% vs 0%), cancer disease (44% vs 12%), multiple myeloma (21% vs 1%), rheumatoid arthritis (14% vs 5%), and treatment with antineoplastic agents and oxycodone. Conclusion: These results lend further evidence to previously identified risk factors for ONJthat is, intravenous bisphosphonate administration; invasive dental procedures and dental prostheses; cancer disease, in particular multiple myeloma; and possibly, long-term bisphosphonate treatment. A putative further risk factor is rheumatoid arthritis. Only long-term bisphosphonate treatment was more common among AF cases. The lack of overlap of risk factors between ONJ and AF suggests different pathogenic mechanisms.
引用
收藏
页码:616 / 624
页数:9
相关论文
共 50 条
  • [31] Consensus practice guidelines for bisphosphonate-associated osteonecrosis of the jaw
    Philip N Sambrook
    Nature Clinical Practice Rheumatology, 2009, 5 : 6 - 7
  • [32] Quality of Life Implications of Bisphosphonate-Associated Osteonecrosis of the Jaw
    Miksad, Rebecca Anne
    Lai, Kuan-Chi
    Dodson, Thomas Benton
    Woo, Sook-Bin
    Treister, Nathaniel Simon
    Akinyemi, Omosalewa
    Bihrle, Marian
    Maytal, Guy
    August, Meredith
    Gazelle, G. Scott
    Swan, J. Shannon
    ONCOLOGIST, 2011, 16 (01): : 121 - 132
  • [33] Bisphosphonate-associated osteonecrosis of the jaw. Diagnostics and therapy
    Voss, P. J.
    Walter, C.
    MKG-CHIRURG, 2013, 6 (02): : 101 - 106
  • [34] CLINICAL EXPERIENCE WITH SPIRAMYCIN IN BISPHOSPHONATE-ASSOCIATED OSTEONECROSIS OF THE JAW
    Gasparini, G.
    Saponaro, G.
    Di Nardo, F.
    Moro, A.
    Boniello, R.
    Cervelli, D.
    Marianetti, T. M.
    Palazzoni, G.
    Pelo, S.
    INTERNATIONAL JOURNAL OF IMMUNOPATHOLOGY AND PHARMACOLOGY, 2010, 23 (02) : 619 - 626
  • [36] Pathophysiology of atypical femoral fractures and osteonecrosis of the jaw
    J. Compston
    Osteoporosis International, 2011, 22 : 2951 - 2961
  • [37] Bisphosphonate-associated Osteonecrosis of the Jaw cases in South Korea.
    Chung, Y.
    Kwon, Y.
    Lee, J.
    Kim, D.
    Lee, S.
    Lee, B.
    JOURNAL OF BONE AND MINERAL RESEARCH, 2008, 23 : S210 - S210
  • [38] Bisphosphonate-associated osteonecrosis of the jaw [Bisphosphonatassoziierte Osteonekrose des Kiefers]
    Abu-Id M.H.
    Açil Y.
    Gottschalk J.
    Kreusch T.
    Mund-, Kiefer- und Gesichtschirurgie, 2006, 10 (2): : 73 - 81
  • [39] Bisphosphonate-associated osteonecrosis of the jaw. A proposal for conservative treatment
    Bocanegra Perez, Sacramento
    Vicente Barrero, Mario
    Sosa Hernandez, Manuel
    Knezevic, Milan
    Castellano Navarro, Jose Maria
    Rodriguez Millares, Jose
    MEDICINA ORAL PATOLOGIA ORAL Y CIRUGIA BUCAL, 2008, 13 (12): : E770 - E773
  • [40] Lack of response to teriparatide therapy for bisphosphonate-associated osteonecrosis of the jaw
    Narvaez, J.
    Narvaez, J. A.
    Gomez-Vaquero, C.
    Nolla, J. M.
    OSTEOPOROSIS INTERNATIONAL, 2013, 24 (02) : 731 - 733